Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.08B 7.94B 7.32B 6.73B 12.75B 873B 12.97B 87.41B 34.3B 427B 34.09B 33.34B 1,472B P/E 2026 *
-15.2x
P/E 2027 * -31.1x
Enterprise Value 8.83B 7.72B 7.12B 6.54B 12.4B 849B 12.61B 84.98B 33.34B 415B 33.14B 32.42B 1,431B EV / Sales 2026 *
9.93x
EV / Sales 2027 * 6.43x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-1.14%
1 week-35.20%
Current month-30.97%
1 month-26.00%
3 months-28.76%
6 months-29.12%
Current year-30.82%
1 week 53.51
Extreme 53.51
70.35
1 month 53.51
Extreme 53.51
86.74
Current year 53.51
Extreme 53.51
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-35.20%+30.31%+29.69% 9.08B
-0.17%+1.47%+3.16%+7.43% 50.35B
-0.29%-2.81%+387.81%+593.12% 39.32B
-0.49%+1.48%+31.16%-6.58% 34.69B
+1.53%+3.11%+15.41%+57.28% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+1.13%-3.11% - - 16.49B
-1.29%-0.52%+69.24%+113.95% 15.31B
+0.43%+3.34%+14.96%+17.98% 13.8B
+2.45%+3.99%+18.20%-29.77% 12.87B
Average +0.44%-4.00%+63.83%+90.05% 25.26B
Weighted average by Cap. +0.43%-1.61%+80.06%+118.71%

Financials

2026 *2027 *
Net sales 889M 777M 717M 659M 1.25B 85.55B 1.27B 8.56B 3.36B 41.82B 3.34B 3.27B 144B 1.4B 1.22B 1.13B 1.04B 1.96B 135B 2B 13.46B 5.28B 65.77B 5.25B 5.14B 227B
Net income -596M -521M -480M -442M -837M -57.32B -851M -5.74B -2.25B -28.02B -2.24B -2.19B -96.57B -296M -259M -239M -220M -416M -28.52B -423M -2.85B -1.12B -13.94B -1.11B -1.09B -48.05B
Net Debt -252M -221M -204M -187M -355M -24.29B -361M -2.43B -954M -11.87B -948M -927M -40.93B -86.16M -75.33M -69.49M -63.88M -121M -8.29B -123M -830M -326M -4.05B -324M -316M -13.97B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-15 US$54.73 -0.36% 3,571,502
26-07-14 US$54.93 -3.21% 4,700,265
26-07-13 US$56.75 -2.58% 5,097,949
26-07-10 US$58.25 -9.37% 11,444,106
26-07-09 US$64.27 -23.90% 20,447,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
54.93USD
Average target price
92.45USD
Spread / Average Target
+68.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock